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Long-lived cancer stem cells (CSCs) with indefinite proliferative potential have been identified in multiple epithelial cancer types.
These cells are likely derived from transformed adult stem cells and are thought to share many characteristics with their parental
population, including a quiescent slow-cycling phenotype. Various label-retaining techniques have been used to identify normal
slow cycling adult stem cell populations and oﬀer a unique methodology to functionally identify and isolate cancer stem cells. The
quiescent nature of CSCs represents an inherent mechanism that at least partially explains chemotherapy resistance and recurrence
in posttherapy cancer patients. Isolating and understanding the cell cycle regulatory mechanisms of quiescent cancer cells will be
a key component to creation of future therapies that better target CSCs and totally eradicate tumors. Here we review the evidence
for quiescent CSC populations and explore potential cell cycle regulators that may serve as future targets for elimination of these
cells.
1. Cancer Induction from Adult Stem Cells
The development of cancer is a complex multistep process
that requires the accumulation of mutations resulting in a
cell acquiring the essential hallmarks of cancer: evasion of
apoptosis, self-suﬃciency in growth signals, insensitivity to
antigrowth signals, invasive and metastatic abilities, limitless
replicative potential, and sustained angiogenesis [1]. Given
that normal adult stem cells already exhibit limitless replica-
tive potential, it is hypothesized that transformed stems cells
may be the cells of origin for many cancers [2, 3]. In addition
to replicative potential, long-lived stem cells have the oppor-
tunity to accumulate oncogenic mutations over years or
decades from commonmutagenic sources like inflammation,
radiation, chemicals, or infection, unlike shorter-lived transit
amplifying (TA) cells that rapidly proliferate and diﬀerentiate
[4, 5]. Like healthy adult stem cells, transformed stem cells
are expected to be able to generate oncogenic TA cells. These
TA cells would be capable of driving tumor formation and
generating the heterogeneous combination of populations
commonly seen in cancer [6, 7]. Transformed stem cells
have been termed cancer stem cells (CSCs), also known
as cancer initiating cells, and are defined as the fraction
of cells within a tumor that are long lived, possess the
potential to proliferate indefinitely, and can generate all
heterogeneous lineages of the original tumor in xenograft
models [6, 8]. CSCs are expected to utilize characteristics
commonly found in stem cell populations such as diﬀerential
metabolic activity, specific signaling pathway activity, and
regulation of cell cycling characteristics, albeit with aberrant
regulation [7, 9] (Table 1). Importantly, CSCs that survive
treatment could account for tumor recurrence as a result
of reactivation of proliferation in surviving CSCs [10].
Traditional chemotherapy regimens target proliferating cells,
potentially missing slower dividing CSCs that must be
eradicated to provide long-term disease-free survival [11]. A
better understanding of CSCs is essential in understanding
the biological and clinical consequences of existing regimens
and designing new therapies to improve patient outcome [9].
Current methods for isolation and study of CSCs rely
on cell surface markers found to be enriched in populations
with stem cell-like properties. This technique was first used
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Table 1: Comparison of characteritics between adult and cancer
stem cells.
Characteristics Adult Stem Cells Cancer Stem Cells
Replicative
Potential
Extensive proliferative
capacity with the
potential to exhaust
regenerative ability
Extensive proliferative
capacity with the
potential to exhaust
regenerative ability
Diﬀerentiation
Ability
All lineages of the
specific tissue
All heterogeneous
lineages within the
original tumor
Metabolic Activity Low Unknown
Signaling Pathway
Hedghog, Wnt,
Notch, and BMP
Aberrant regulation
of Hedghog, Wnt,
Notch, BMP, and
others
Cell Cycling
Regulation
Slow cycling, tightly
controlled
Potentially slow
cycling, unknown
Location
Niche:
Compartmentalized
or associated with
stromal layer
Unknown
Adhesion Tightly Adhesive Unknown
Migration
Potential
No/Slow Migration
Epithelial to
Mesenchymal
Characteristics
by Bonnet and Dick in 1997 when they demonstrated that
only the CD34+CD38− subset of cells were capable of ini-
tiating human acute myeloid leukemia (AML) in immune-
compromised mouse models [12]. Since the work of these
two pioneers, CSC populations have been identified in mul-
tiple epithelial cancers including the breast [8], prostate [13],
pancreas [14], colon [15–17], ovaries [18], and brain [19].
Unfortunately, the use of CSC markers has not been
without controversy. One issue centers on uncertainty of
the functional implications of CSC markers and is best
exemplified by the use of CD133 in the identification of colon
CSCs. Shortly after Ricci-Vitiani et al. (2007) demonstrated
the use of the CD133 to identify CSCs in colon tumor,
Shmelkov et al. demonstrated that CD133 expression was
not restricted to colon CSCs, but that CD133 is expressed on
diﬀerentiated colonic epithelium in both mice and humans
[16, 20]. Reasons behind this contradiction of data still
remain unclear, but Kemper et al. methodically evaluated
the CD133 antibodies used by both groups and reached the
conclusion that the AC133 epitope used by Ricci-Vitiani et al.
recognized a diﬀerentially expressed form of CD133 that is
not recognized by the antibody used by Shmelkov et al. [21].
It appears that CD133 is expressed in all colon epithelium,
while the AC133 epitope is specific for the CSC phenotype.
Furthermore, Kemper et al. were unable to determine
the functional significance of the diﬀerentially expressed
isoforms of CD133, highlighting another drawback to the
use of markers to identify CSCs. Very little is known about
the function of many of the proposed CSC markers, and
even less is known about the functional implications they
may have for the CSC phenotype. At best, markers without
functional implications must be viewed as only tools for stem
cell enrichment, suggesting the need for a more functionally
significant means of CSC identification [22]. Given the sim-
ilarities between normal adult stem cells and CSCs, aberrant
regulation of self-renewal and quiescence is likely central to
CSC pathology [9, 10]. Targeting pathways that mediate stem
cell quiescence is therefore an intriguing alternatemethod for
CSC identification and use in future therapy.
The primary objectives of this paper are to place quies-
cent label-retaining studies in the context of what is currently
known about adult stem cells and then review the existing
evidence for quiescence in cancer stem cells. We will examine
current evidence for the role of quiescence in CSC resistance
to conventional cancer therapy and recurrence. Finally, we
will explore current knowledge of quiescence regulation and
how these studies might be considered when developing
CSC future experiments to develop targeted therapies against
CSCs.
2. Adult Stem Cells and Quiescence
Adult stem cells are critical for continued normal tissue
homeostasis and response to wounding for many of the
epithelial tissues of the body. Adult stem cells are character-
ized by their ability to self-renew indefinitely and produce
progeny capable of diﬀerentiating and repopulating tissue
specific lineages [7]. Populations of adult stem cells have
been identified in tissues throughout the body, including the
skin [23–25], mammary glands [26, 27], intestine [28, 29],
prostate [30], brain [31], and the hematopoietic system
[32, 33]. In tissues where cells are frequently lost to the
environment, like those of the intestine and skin, new cells
are continuously required to replenish those that are lost.
To facilitate this constant need for new cells, some epithelial
tissues are arranged hierarchically with slowly proliferating
stem cells that asymmetrically divide to give rise to a new
stem cell and a rapidly dividing transit amplifying (TA)
cell [34]. Transit amplifying cells proliferate quickly for a
limited number of divisions, allowing for the high degree of
cell turnover necessary to sustain adult tissues. Infrequent
division or a quiescent nature is not definitive for adult
stem cell but is suggested to be important for maintenance
of many adult stem cell pools. Evidence suggests that
quiescence may play an important role in protecting stem
cells from exhausting their proliferative capacity, inhibiting
diﬀerentiation, and limiting accumulation of mutations
during frequent rounds of DNA synthesis [35–37].
Initial eﬀorts to identify and study adult stem cells took
advantage of the slow-cycling nature of stem cell populations
in studies employing pulse/chase methodology [23, 28]. In
these studies, tritiated thymidine (3H-TdR) or 5-bromo-2-
deoxy-uridine (BrdU) was repeatedly administered to mice
or cultured cells that were then followed by an extended
period of chase time. During this chase period, rapidly
proliferating TA cells divide the label between daughter cells,
consequently diluting the label (Figure 1). In contrast, slow-
cycling stem cells undergo few divisions and retain detectable
quantities of label formuch longer periods of time. Cotsarelis
et al. demonstrated that label retaining cells (LRCs) were
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Figure 1: Pulse Chase Labeling and Chemotherapy Survival of Stem Cells. (a) Cell suspensions are labeled with BrdU or other label ((i) and
(ii)). As rapidly proliferating transit amplifying cells divide, label is diluted among the daughter cells and eventually becomes undetectable
(iii). Slow dividing stem cells retain label occasionally producing a new transit amplifying cell that will quickly dilute out residual label (iv).
(b) Heterogeneous tumors are predicted to contain a population of slow cycling label retaining cells (i). Conventional chemotherapies target
and kill rapidly proliferating cells, while quiescent cells survive ((ii) and (iii)). Cancer stem cells that survive chemotherapy re-enter the cell
cycle and re-establish the tumor.
exclusively present in the bulge area of the mouse hair
follicle [23]. These cells were found to be relatively stem-like:
“primitive” in cytoplasmic contents, structurally similar to
other putative stem cell populations, and could be stimulated
to proliferate. We utilized human skin xenografted onto
immunodeficient mice to show that LRCs were present in an
analogous bulge region of human skin delineated by keratin
15 (K15) expression [24]. Cells present in the bulge region
have been experimentally shown to be quiescent for up to
1 year [38], and based on the hair growth cycle of scalp
skin can likely remain quiescent for up to 5 years. Using
the K15 promoter to drive expression of EGFP or lacZ,
K15 positive cells were found to diﬀerentiate into all major
epithelial lineages of the mouse skin [39]. We demonstrated
that K15+ bulge cells from human skin can diﬀerentiate into
epidermal, sebaceous, and hair follicle lineages in vitro [40].
Array analysis of the LRC bulge population showed increased
activation of Smad and inhibitors of the Wnt pathway,
suggesting the ability for LRCs to organize their niche and
communicate with neighboring mesenchymal and epithelial
cells, an important characteristic for stem cell function [41].
The work in our lab and others supports a model in
which the bulge region of hair follicles represents the stem
cell niche in skin. At the onset of the growth phase (anagen)
hair follicle stem cells are activated and produce matrix TA
cells that proliferate and diﬀerentiate into the seven diﬀerent
lineages found within the hair follicle. As matrix TA cells
exhaust their proliferative potential they enter a state of
destruction (catagen) leading to the loss of the majority of
the hair follicle excluding the bulge. Catagen is followed by a
period of rest (telogen) in which the bulge stem cells remain
quiescent until activation into a new anagen stage [2].
Although likely important for the maintenance of the
stem cell pool, quiescence may not be a requirement for
adult stem cells. Using a lacZ construct under a conditional
promoter for the stem cell-associated protein leucine-rich G
protein-coupled receptor 5 (Lgr-5), Jaks et al. demonstrated
a distinct nonlabel retaining subpopulation of bulge cells
that overlap with the CD34+/K15+ at telogen but not anagen
[42]. Lineage tracing techniques confirmed that Lgr-5+
cells actively cycled during normal homeostasis and had a
multipotent phenotype. The authors of this paper suggest
that the Lgr-5+ population of cells represents a cycling
population of stem cells under normal conditions, whereas
the label retaining CD34+/K15+ stem cells may represent a
reserve population that is activated after tissue damage. As
yet, a conclusive relationship between these two populations
cannot be firmly established.
Similar label-retaining methods have been used to study
slow-cycling cells in other tissues, such as the small intestine
and colon. Work conducted by Potten and colleagues
identified slow-cycling LRCs at the +4 position at the base
of the colon crypt. These crypt base cells were found to be
maintained in a steady state of between four and six cells that
go through division approximately once a week [43]. Upon
irradiation, these cells demonstrated increased antiapoptotic
bcl-2 expression, decreased p53 expression and were highly
activated and involved in clonogenic regeneration of the
crypt. Detailed biochemical analysis of this population
has been limited by the absence of reliable markers and
methods capable of suﬃciently isolating these cells. Two
studies involving the putative stem cell-associated RNA
binding protein Musashi-1 (Msi-1) have both demonstrated
colocalization of this protein with colon LRCs, but fell short
4 Journal of Oncology
of testing for clonogenicity of this population [44, 45].
Similar to stem cell populations in the skin, β1-integrin
was found to be highly expressed in the lower half of the
colonic crypt [46]. When sorted via flow cytometry, β1-
integrin showed enrichment for clonogenic cells; however,
an exact colocalization pattern with LRCs was not evaluated,
and therefore, the connection remains only speculative.
From the evidence collected in these studies and others, a
model has been suggested in which slow-cycling stem cells,
found at the base of the crypt, undergo periodic division
to give rise to TA cells. Transit amplifying cells low in the
crypt undergo rapid division and slowly progress up the
crypt, losing replicitative potential and diﬀerentiating as they
increase in crypt height. These cells are ultimately lost to the
environment [6, 43].
As within the hair follicle, there is convincing evidence
for an Lgr-5+ nonlabel retaining population of colon stem
cells additionally found at the base of the crypt [29]. While
the LRCs reside at the +4 population, Lgr-5 cells are observed
as slender wedge-shaped cells at the +2 position. Again, the
exact relationship between the LRCs and the Lgr-5+ cells
is yet to be fully explored, and more data into the lineage
potential of both of these cell populations is needed to form
a cohesive model.
Since the early identification of colon and hair follicle
slow-cycling stem cell populations, label-retaining tech-
niques have been used to identify and validate putative
stem cell populations in multiple epithelial tissues. In the
mammary gland, three separate label-retaining populations
have been identified and proposed as possible stem cells.
In a study conducted by Welm et al., LRCs were found to
comprise a subpopulation of stem cell antigen-1 positive
(Sca-1+) cells [26]. These Sca-1+ cells were found to be
enriched for the ability to form outgrowths, leading the
authors to speculate that the LRCs might represent the
stem cell population contained within the Sca-1+ cells. In
contrast to this study, Shackleton et al. identified a long-term
label-retaining population enriched by the marker combi-
nation Lin −CD29hiCD24+ that was able to reconstitute a
functional mammary gland from a single cell [27]. The
Lin−CD29hiCD24+ did not enrich for the Sca-1 population,
prompting other groups to suggest a stem cell hierarchy in
which multiple layers of stem cells exist within the mammary
gland [47]. Using a slightly diﬀerent methodology, Pece used
the lipophilic fluorescent dye PKH26 to identify a population
of mammary label retaining cells [48]. The use of the PKH26
allows for live sorting of LRCs, which is not possible using the
nucleotide analogue BrdU and 3HT-TdR that both require
permeabilization of the cell membrane for antibody labeling.
Live sorting of PKH26 LRCs demonstrated increased in vitro
sphere formation eﬃciency and regeneration of cleared fat
pads over non-LRCs. Pece was also able to conduct tran-
scriptional analysis of the LRC population, from which he
created a human normal mammary gland stem cell signature
(hNMSC) consisting of the markers CD49F/DNER/DLL1.
Unfortunately, the exact relationship between the diﬀerent
populations identified by these three groups is not yet clear.
In the brain, high doses of 3H-TdR kill all but one per-
cent of proliferating subependymal. High dose therapeutics
did not aﬀect the capacity of quiescent cells to generate
spheres in vitro or repopulate the proliferating population
in vivo. The ability to survive and re-enter the cell cycle
suggests a stem cell phenotype for these quiescent cells [49].
Prostate slow-cycling LRCs located in the proximal ducts
demonstrated high proliferative potential and the ability to
reconstitute the prostate glandular structure in vitro. This
ability singles them out as stem cells over more rapidly
cycling TA cells located at the distal region of the ducts [50].
Finally in the pancreas, characterization of LRCs around
the acini and ducts suggested a stem cell population by
demonstrating increased expression of the putative stem cell
marker c-Met and activation in response to damage to form
duct-like structures [51].
Combined, these data indicate an important role for
quiescent LRCs in maintenance and longevity of multiple
adult epithelial tissues.
3. Quiescence and CSCs
If CSCs do originate from normal adult stem cells, then it
is foreseeable that key stem cell regulatory traits are retained
through the oncogenic transition; quiescence is potentially
one of these traits. Little research has been done to address
how quiescence might play a role in CSC biology, but there
are some indications that quiescent stem-like populations
might contribute to at least some tumors. We previously
identified a subpopulation of cells in human sebaceous
tumors that expressed the skin stem cell marker keratin 15
[52] (Figure 2). These cells appeared to have variable expres-
sion of the proliferation marker Ki-67, suggesting a low but
higher proliferative rate than normal stem cells. In primary
ovarian tumors, Gao et al. demonstrated that CD24+ cells
expressing stem cell-associated genes like nestin, oct4, and
both notch1 and notch4 were more slowly proliferating than
the bulk tumor cells suggesting a quiescent phenotype [18].
Low numbers of slowly proliferating CD24+ cells were shown
to produce tumors in a xenograft model where bulk cells
were found to be nontumorigenic. This data implicates a link
between quiescence and ovarian tumor CSCs.
Pece also observed a link between CSCs and quiescence in
breast tumors [48]. Using the hNMSC signature generated
with normal mammary LRCs, Pece turned his attention
to the analysis of primary breast tumors, finding that the
hNMSC signature was more commonly found in grade 3
tumors over that of grade 1. When grade 1 and grade 3
mammospheres were analyzed for PKH label retaining cells,
both populations were found to retain label, with grade
3 tumors demonstrating a higher percentage. This data
suggests an increase in stem-like cells as tumors progress.
When evaluated for tumor genicity, breast tumor cells
positive for the hNMSC signature were more eﬃcient at
forming in vitro spheres and in vivo xenograft tumors that
those cells lacking the hNMSC signature.
Cultured cancer cell lines are often used to study
signaling pathways, invasion, migration, and apoptosis, but
are rarely thought of as candidates for CSC studies. Many
of the most widely used cell lines have been in passage for
years, are perceived homogeneous, lack interactions with the
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Figure 2: Stem cell markers in Normal Sebaceous Gland and Sebaceous Tumor. Immunohistochemical staining for the skin stem cell marker
Keratin 15 (K15). (a) Normal skin sebaceous gland with labeled stem cells (black arrows). (b) Sebaceous tumor with heterogeneous
expression of K15.
appropriate stromal microenvironment, and change charac-
teristics based on alterations in culture conditions. Therefore,
cultured cell line studies assessing CSC characteristics must
be evaluated critically, with data interpreted within the con-
text of the experimental parameters, and results confirmed
under biologically relevant conditions. Still, interesting work
in the cultured tumor lines MCF10A, MCF7, SUM149,
SUM159, SUM1315, and MDA.MB.231 suggests that these
lines may not be as homogenous and void of “stem like” cells
as once thought [53]. CD44+/CD24−/ESA+ cells within these
lines were found to contain the ability to self-renew, recon-
stitute the parental line, and to be up to 90% label retaining.
If LRCs are found to retain the CSC phenotype in cultured
cell lines, these cell lines may provide an important resource
for future delineation of quiescent pathway regulators.
Additional transitive evidence linking quiescence to CSCs
can be found in the work conducted by Roesch et al. in
melanoma [54]. This group found that primary melanoma
cell lines contained a PKH26 label retaining population that
was almost specifically identified by the H3K4 demethylase
JARID1B. This population of cells was found to incorporate
BrdU more slowly but retain it for a longer period of
time, lack Ki67 staining, and have a doubling time of up
to 4 weeks in vitro. When EGFP was placed under the
control of the JARID1B promoter, GFP+ cells demonstrated
increased sphere forming ability in vitro. Interestingly, GFP+
cells were able to retain BrdU in vivo, but did not show
increased tumor initiating ability over GFP− cell during
the time period analyzed. Small hairpin RNA (shRNA)
knockdown of JARID1B resulted in the in vitro exhaustion of
proliferating cells, demonstrating the need for JARID1B cells
in maintenance of proliferative capacity but not initiation
of tumors. When assessed more fully, both in vitro and in
vivo GFP− cells gave rise to heterogeneous progeny, including
JARID1B GFP+ cells.
The most direct evidence to date for quiescence playing a
role in CSCs comes from a study conducted by Dembinski
and Krauss [55]. In this study Vybrant DiI cell-labeling
solution was used to label pancreatic adenocarcinoma cells
and conduct cancer stem studies on flow cytometry sorted
label retaining cells. DiI label retaining slow-cycling cells
(DiI+/SCCs) comprised ∼3% of total cell number. Interest-
ingly, label retaining cells also exhibited an elongated fibrob-
last shape and an increase in the epithelial-mesenchymal
transition markers vimentin, snail, and twist. A fibroblast-
like CSC is consistent with evidence demonstrating an
increase in stem-like properties in cells that have undergone
an epithelial-mesenchymal transition [56]. Furthermore,
sorted DiI+/SCCs demonstrated a 2.5–10-fold increase in
soft agar colony forming ability, twofold increase in invasive
potential, and more than a tenfold increase in xenograft
formation over nonlabel retaining cells. Combined, these
data suggest that DiI+/SCCs cells represent an enriched CSC
population. When assessed for common CSC marker status,
DiI+/SCCs were enriched but only partially overlapped with
CD24+/CD44+ and CD133+ populations. It is curious to
consider how these commonly used CSC markers relate to
the LRC populations and what role, if any, these markers play
in the slow-cycling phenotype?
Like the melanoma study by Roesch et al. [54], Dem-
binski and Krauss’s study also indicated the ability for LRCs
to produce non-LRCs and surprisingly also for non-LRCs
to produce LRCs. Such a dynamic suggests two possibilities
(1) that the true unknown CSC population is favored
in the LRCs, but also found in the non-LRCs and can
therefore give rise to both populations, or (2) that there
exists a dynamic relationship in LRC-CSC populations that
is context dependent and allows for interconversion between
the two states. The Dembinski and Krauss study argues
a dynamic population of CSCs that might coincide with
an epithelial-mesenchymal transition (EMT). EMT plays a
central role in embryogenesis and mesoderm diﬀerentiation
into multiple tissue types during development [56]. The
emergence of embryonic stem cell-associated genes like
nanog, oct4, sox2, and c-myc in high grade undiﬀerentiated
cancers is suggestive that aberrant regulations of EMT and
other early development pathways might be playing a role in
CSC characteristics [57]. This data is a further evidence to
support a dynamic quiescent slow-cycling model for many
types of cancer. Future studies will be important for further
development and integration of these observations into the
CSC model for tumor initiation and propagation.
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4. Quiescence and Resistance to Chemotherapy
At the present time, we have no clear understanding of why
some patients recur and which cancers will have resistance
to conventional types of therapy. Tumors from diﬀerent
patients in the same organ are likely to have undergone
diﬀerent oncogenic transitions, leading to a diversity of pos-
sible regulatorymechanism and pathway activities thatmight
be contributing to the survival of a specific cancer. While
broad patterns like the dysregulation of the Wnt pathway
in colon carcinomas are commonly observed, the secondary
mutations that may accompany these cancers could be
vastly diﬀerent and contribute to survival in diﬀerent ways
[58]. Even within the same tumor, diﬀerent CSCs have
the possibility to accumulate unique mutations that may
provide added resistance and be passed on to daughter cells.
In context with the vast diﬀerences in tumorigenesis and
heterogeneity with a tumor, it is not surprising that the exact
contributors to chemotherapy resistance and consequently
which patients will respond optimally to chemotherapy are
not well understood. It has been proposed that variations
in cell cycle control, antiapoptotic proteins, increased DNA
damage repair proteins, upregulation of cellular pumps, and
increased metabolic activity may all play important roles in
chemotherapy resistance [6, 59–62].
Conventional chemotherapies and radiotherapies target
proliferating cells and require active cycling for induction
of apoptosis. The quiescent nature of many adult stem cell
pools is therefore an inherent mechanism for resistance and
cell survival to conventional therapies. In the hematopoietic
system, normal hematopoietic stem cells (HSCs) contain
high levels of the quiescence regulator p21cip1/waf1 (p21)
[63]. When treated with the commonly used chemotherapy
agent 5-fluorouracil (5-FU), mice that were p21 deficient
had a significant decrease in cobblestone area-forming
stem cells (10.8%) than normal p21 expressing wild-type
mice (60.5%). In the brain, Morshead et al. demonstrated
that high doses of tritiated thymidine (3H-TdR) killed
the constitutively proliferating cells in the adult mouse
forebrain, but had no eﬀect on quiescent stem cell ability to
generate spheres [49]. This data supports a model in which
quiescent mouse forebrain stem cells are able to survive
and re-enter the cell cycle to allow for regeneration of the
damaged tissue. A similar pattern of stem cell survival and
regeneration was observed 72 hours following doxorubicin
treatment in mouse intestine. In this experiment, mice
intestine demonstrated increased amounts of cell death via
apoptosis in the +3–6 positions and a parallel disappearance
of mitotic activity [64]. This period of relatively nonexistent
mitotic activity was followed by stem cell re-entry into the
cell cycle and tissue regeneration in the +4 position stem
cell compartment. Furthermore, colon stem cell survival
during chemotherapy is aided by increased expression of
BH3-only bcl-2 members that inhibit apoptosis, working in
parallel with quiescence to increase the likelihood of stem cell
survival [65]. In chemotherapy-induced alopecia, the rapidly
dividing TA cells in the hair matrix undergo apoptosis, while
the stem cells in the bulge region survive to regenerate the
follicle after chemotherapy is withdrawn. Potential factors
involved in regulating hair follicle stem cell survival such as
caveolin-1 are emerging [66].
Similar mechanisms for survival and self-renewal for
CSCs are plausible in instances of tumor recurrence in
human patients where cytotoxic agents kill proliferative
cancer cells, leaving quiescent slow-cycling [6]. Cancer stem
cells that survive chemotherapy would have the ability to re-
enter the cell cycle and produce highly proliferative-rapidly
dividing progenitor cells that can re-establish the tumor. It is
even probable that successive cycles of chemotherapy would
intensify a tumor by weakening the normal stem cell pool
and creating therapy resistant CSCs that give rise to resistant
oﬀ-spring [9].
Slow cycling CSC populations in the colon, breast,
ovaries, and pancreas have been shown to demonstrate both
in vivo abilities to survive therapies that kill bulk tumor
cells as well as a requirement for doses of up to twice that
which are required to kill rapidly proliferating cells in vitro
[18, 55, 62, 67]. These data demonstrate how ineﬀective
conventional therapies can be on quiescent cell populations
and help to explain why tumors that seem to fully regress
during treatment can recur. While large tumor populations
may appear to have totally regressed after treatment, single
surviving CSCs would not be detectable with current
diagnostic technology. Populations of CSCs that are resistant
to chemotherapy or radiation are able to re-enter the cell
cycle or never fully undergo cell cycle arrest and are primed
to re-establish tumors [53, 68]. Even more devastating to
the survival of patients may be CSC response to stress from
chemotherapy and radiotherapy. Mouse ovarian tumors
have been demonstrated to undergo accelerated clonogenic
production during radiotherapy regimens, expanding the
CSC pool and driving development of a more aggressive
secondary tumor [69]. Furthermore, these cells would be
more likely to produce chemotherapy resistant oﬀspring,
rendering the tumor unaﬀected by later rounds of treatment.
While quiescence is likely to contribute to the survival
of CSCs in response to chemotherapy and radiation, slow
cycling is not the sole mechanism and in all likelihood works
in parallel with other systems to increase survival. Msi-1+
colon cancer cells have been demonstrated to be less sensitive
to cytotoxic drugs due to increased IL-4 expression and
orchestration of antiapoptotic mechanisms [70]. The expres-
sion of other antiapoptotic proteins like c-Flip and Bcl-2 BH-
3 only family members is frequently seen in stem cell and
CSC populations and has been demonstrated to contribute
to cell survival during radiation and chemotherapy [59, 60].
Reduced cycling may help to limit cell damage in these cases,
decreasing prodeath signals and increasing the potential for
CSC survival.
Additional mechanisms for CSC survival include incre-
ased DNA damage repair, upregulation of cell pumps like the
multidrug resistance transporter (MDR1) and the Adeno-
sine triphosphate-binding cassette (ABCB1), and increased
metabolic activity through ALDH [61, 62]. Although the
quiescence contribution to these mechanisms of resistance is
unclear, it is likely that reduced proliferative rate only adds
to their eﬀectiveness. Additional time in S or G2 phase of
the cell cycle coupled with increased DNA repair protein
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activity may aﬀord a survival advantage over bulk cells that
continuously accrue DNA damage and ultimately are forced
to undergo apoptosis. Reduced cycling speed together with
increased pumps would facilitate more drug being removed
from CSCs, limiting overall cytotoxic eﬀects during the
period of treatment. Additionally, quiescence would allow for
increased metabolic activity of ALDH and other metabolites
over that of bulk cells with a shorter cell cycle period.
Importantly, there is no reason why combinations or all of
these resistance mechanisms could not be playing a role in
CSC survival. Future therapies may need to address all these
issues to be successful in complete tumor eradication.
5. Regulators of Quiescence
Given the importance of quiescence in the CSC contribu-
tion to tumor progression and survival, understanding the
mechanisms that govern quiescence will prove important in
the development of future strategies to better target these
cells. Much of our current understanding of the mechanisms
controlling quiescence come from studies using conditional
induction of quiescence in normal adult fibroblasts. The
induction of quiescence in fibroblasts is generally accom-
plished in one of three ways: mitogen deprivation, contact
inhibition, or loss of adhesion. Each method of inducing
quiescence in fibroblast appears to yield a diﬀerent quies-
cent transcriptional program [35]. The three transcription
programs overlap in diﬀerential expression of 131 genes
that Coller et al. have designated a “quiescence signature.”
This signature is comprised of genes that regulated cell
growth and division, suppress apoptosis and diﬀerentiation,
and govern intercellular communication. Downregulated
elements in the quiescence signature consist of genes asso-
ciated with cell cycle progression including cyclin B1, cdc20,
cul-1, and myc. Up regulated genes included important cell
cycle regulators like TP53 (p53), cyclin D2, and MXI1. Also
up regulated in this signature are regulators of key stem
cell-associated pathways including the Wnt pathway (FZD2
and TCF7L2), the BMP pathway (SMAD1), and the Notch
pathway (Hes1). Notch activation of Hes1 is of particular
interest as it has been shown to control reversibility of
fibroblast quiescence by blocking diﬀerentiation and entry
in irreversible cell cycle arrest [36]. Notch pathway activity
is important in mammary gland development as well as the
mammary CSC response immediately following irradiation,
suggesting that the Notch pathway may be a potential target
in CSCs [5, 71].
Interestingly, there exists a fourth transcriptional pro-
gram in fibroblasts induced by overexpression of cyclin-
dependent kinase inhibitors (CKI) like p21 and p16INK4a
[35]. The CKI p21 has been found to control entry into qui-
escence andmaintenance of the quiescent state, allowing cells
to activate a DNA damage-like response [72]. Additionally,
maintenance of fibroblast quiescence has also been shown to
be highly regulated by the retinoblastoma family members
Rb and p107 [73]. Loss of Rb and p107 did not aﬀect the
ability of fibroblasts to enter G0, but these cells were unable
to maintain the quiescent state. While Rb loss is generally
associated with the progression of cancer, retention of Rb in
CSCs or contribution of other Rb family members like p107
may be important in CSC maintenance of quiescence.
Developing and studying a quiescence signature in
fibroblasts may be important in understanding regulation of
the cell cycle, but the exact relevance to quiescent stem cell
populations is not very clear. Primarily, quiescence fibroblast
studies are conducted on large populations of fibroblasts
under biologically stressful conditions like contact inhibition
or serum starvation. In contrast, individual stem cells and
CSCs maintain quiescence while in contact with daughter
cells and stromal layers and in the presence of normal
mitogenic signals. Additionally, sphere forming assays com-
monly used for the identification of stem cells and CSCs rely
specifically on proliferation under nonadherent conditions.
If mitogen deprivation, loss of adhesion, and contact inhi-
bition truly activate three diﬀerent transcriptional programs
in quiescent fibroblast populations, it is possible that the
transcriptional program facilitated by quiescent stem cells
and CSCs may be very diﬀerent.
Quiescence regulation of a stem cell population is most
comprehensively understood in the hematopoietic system.
When compared to diﬀerentiated or cycling HSCs, quiescent
HSCs were found to have up-regulated genes associated with
cell cycle regulation, translation and RNA processing, and
metabolic process [74]. Down-regulated genes were generally
associated with transcription factors, signaling proteins, cell
cycle proteins, and inhibitors of cell cycle progression. In line
with these findings, the CKI p21 was found to be necessary
for quiescence and maintenance of the HSC pool [63]. Mice
that are p21 null demonstrate an increase in the number
of stem cells present and lose the ability to repopulate the
bone marrow in serial transplant experiments, suggesting
uncontrolled expansion and eventual exhaustion of the stem
cell pool. This deregulation of the stem cell pool is likely
due to p21 downstream eﬀects on Rb family members: Rb,
p107, and p130. Rb family members play important roles in
regulating E2F activity and G1/S transition. Triple knockout
of these three family members resulted in hematopoietic
progenitor G1/S transition and proliferation, leading to
exhaustion of the proliferative potential, similar to that seen
in p21 loss [37].
While p21 also appears to play a role in adult neural
stem cell regulation and maintenance, other factors have
been shown to be important contributors to quiescent stem
cell activation [75]. Occasional exit of neural stem cells
from the quiescent state is important for proper tissue
maintenance and may be controlled though notch signaling
via Hes1 oscillations [76]. Down-regulation of Hes1 in
neural progenitor cells during G1 phase reduced repression
of cyclinD, ngn2, and Dll1, activating Notch signaling and
driving cell cycle progression and generation of neural
progenitors. Neural progenitors and neurons continue to
retain low levels of Hes1 as they proliferate and diﬀerentiate.
In neural stem cells, Hes1 expression and control of cyclinD
and notch signaling increase until subsequent G1 entry.
Interestingly, p21 loss does not appear to play a significant
role during diﬀerentiation in the brain, suggesting the need
for additional means of cell cycle regulation in diﬀerentiated
senescent cells [37].
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Signaling pathways with interactions to other CKIs also
play important roles in quiescent adult stem cell regulation.
In mammary glands, the Hedgehog pathways components
Gli2 and Bmi-1 have been demonstrated to regulate stem
cell self-renewal [77]. When injected into cleared mammary
fat pads, Gli2 or Bmi-1 over expressing mammospheres
were able to produce substantially more outgrowths than
control mammospheres. Bmi-1 has been demonstrated to
transcriptionally repress the p16INK4a and p19ARF, suggest-
ing a role for Bmi-1 in mammary stem cell cycle con-
trol.
Additional signaling pathways have been demonstrated
to play important roles in stem cell quiescence, specifically
the BMP pathway in skin. BMP and calcineurin signaling
up-regulate the transcription factor NFAT1c that has been
found to highly colocalize with CD34+ cells in the hair follicle
[78]. NFAT1c represses transcription of CDK4, stalling cells
in G1/S phase and maintaining quiescence. Loss of NFAT1c
permits entry into the cell cycle, shortening telogen and
prompting aberrant entry into anagen.
While significant advances are being made in under-
standing quiescence control in normal adult stem cell
populations, much less is known about control of quiescent
CSC populations. Very few studies have been conducted
specifically addressing control of quiescent CSCs, most likely
due to the diﬃculty of isolating and analyzing pure CSC
populations. If CSCs are truly derived from adult stem
cells, then it is possible that Hes1, p21, p16INK4a, Rb family
members, Bmi-1, and NFAT1c play significant roles in CSC
regulation. Although rare, there are clues that at least some
of these regulators are important in CSCs. In the colon
cancer cell line HCT116, p21 null cells were found to produce
tenfold smaller tumors in growth assays when compared
to normal cells expressing p21 [79]. Under sphere forming
conditions, p21 null cells were unable to form spheres, ceased
proliferation, and eventually died. This p21 dependence was
found to be associated with lack of E-cadherin expression
and suppression of apoptosis signals, suggesting a more
complex role for p21 in tumor cells than simply regulating
cell cycle. Small molecule targeting of p21 or downstream
p21 targets may therefore prove to be an eﬀective means
of forcing quiescent CSCs to cycle or undergo apoptosis.
Cycling CSCs would be susceptible to chemotherapy and
hopefully eliminated.
Cancers frequently have aberrant signaling in the Wnt,
Hedgehog (Hh), and Notch self-renewal pathways that likely
contribute to cell cycle control and diﬀerentiation. Increased
expression of Hes1 has been observed in ovarian, breast, and
nonsmall cell lung carcinomas, suggesting active regulation
of Notch signaling [36]. In melanoma, the slow cycling
cells identified by Rosech et al., repress notch signaling
directly though JARID1B interaction with the notch lig-
and Jagged 1 promoter, consequently reducing intracellular
Notch and controlling proliferation [54]. Hes1 and Jagged1
may therefore be potential targets in future cancer treatments
designed to target CSCs. Targeted reduction of Hes1 would
increase Notch signaling, driving CSCs to proliferate and
exhaust their proliferative potential, and making them more
susceptible to conventional therapy.
In colon cancers, mutations in APC or β-catenin are
considered to be a driving force behind transformation [6].
In the presence ofWnt signal, β-catenin is no longer taken up
by an APC-dependent degradation complex and translocates
to the nucleus where it binds TCF/LEF transcriptions factors
to control expression of cell cycle target genes. Loss of
APC in crypt Lrg5+ cells has been demonstrated to be an
important step towards initiation of intestinal adenomas
[80]. Interestingly, cells expressing high Wnt downstream
transcription factors TCF/LEF in primary sphere cultures
demonstrated increased clonogenicity and the generation
of both cycling and noncycling cells [81]. In tumors, these
high Wnt expressing cells were located near stromal fibrob-
lasts that provided signals to activate β-catenin-dependent
transcription. This data suggests that CSC cell cycle control
may not be entirely cell autonomous and partially regulated
by microenvironmental signals. Targeting Wnt pathway
regulators or the ability for CSCs to communicate with their
stromal environmentmay represent potential mechanism for
limiting CSC expansion and contribution to recurrence.
There is also mounting evidence for the requirement of
Hedgehog signaling in proliferation and survival of both
colon and breast tumors. Active Hh-Gli signaling was found
to contribute to the subpopulation of human colon CD133+
cells that were able to survive and self-renew in xenograft
studies. In breast tumor CD44+/Cd24− cells, the Hh pathway
proteins Patch (PTCH1), Gli1, Gli2, and Bmi-1 all demon-
strated increased expression over bulk tumors cells [77]. Like
their adult mammary stem cell counterparts, overexpression
of Bmi-1 in mammary CSCs suggests a potential role for
p16INK4a and p19ARF in cell cycle regulation and suggests a
potential drug target for improved CSC eradication.
While p21, p16, Notch, Wnt, and Hedgehog signaling
may provide tempting targets for the removal of CSCs, tar-
geting of these pathways would require meticulous targeting
of CSC or titration of inhibitors to act on CSCs but not
normal stem cell populations. Such treatments could severely
weaken patients. Additionally, improper application of cell
cycle inhibitors like p21 may fuel tumor growth and aggres-
siveness. The CDK inhibitor p21 acts as a tumor suppressor
in dividing cells by protecting against genome instability and
working with other tumor suppressors to subdue oncogenes
[82, 83]. Loss of p21 combined with chemical induction
of carcinogenesis has demonstrated increased induction of
tumors and increased aggressiveness in resulting tumors
[84, 85]. Combining widespread targeting of p21 with
chemotherapy may have similar eﬀects of tumors. These data
highlight the necessity to be able to selectively target CSCs
when using CDK inhibitors and add to the challenges ahead
in developing treatments to better eradiate CSCs.
6. Conclusions and Future Directions
The limited data available on the regulation of quiescence
equates to a poor understanding for the role of quiescence
in tumor progression and recurrence. Exactly how and to
what extent quiescence plays a role in tumor recurrence
is at present unclear. What little evidence there is suggests
that quiescence might be an important factor in tumor cell
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survival after conventional therapy. Mechanistically, CSC
quiescence suggests an inherent means of resistance that
when coupled with increased DNA repair or metabolic
activity could explain the patterns of recurrence and acquired
resistance currently observed in posttherapy cancer patients.
The functionally relevant identification of quiescent CSCs
though label-retaining assays may prove to be an important
tool in ongoing CSC research.
Future research must focus on better understanding
and targeting of quiescent CSC populations, specifically
identifying regulators and factors that separate CSCs from
normal stem cells. General targeting of p21, Bmi-1, Hes1,
and other commonly shared cell cycle regulators might prove
disastrous for patients if these treatments eradicate normal
stem cell populations as well as CSCs. Aberrant regulation of
normal stem cell characteristics presents a diﬃcult paradox
in fighting CSCs: how to target the cancer without harming
normal stem cells. Hope exists that careful study of CSCs
will identify new or diﬀerentially expressed targets that will
specifically aﬀect tumors, minimizing toxic side eﬀects and
leaving patients cancer free.
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